MedTrace Logo

Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®

NCT01901458 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-03-19

No results posted yet for this study

Summary

The study will determine the advantage of the Spectra Optia® IDL set compared to the standard collection set for collection of peripheral blood progenitor cells using the Spectra Optia® apheresis system. The study will assess the reduction of apheresis time to obtain the required amount of hematopoietic progenitor cells.

Conditions

  • Healthy Allogeneic Donors
  • Granulocyte Colony-stimulating Factor (G-CSF) Mobilized

Interventions

DEVICE

Spectra Optia® IDL-Set

Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator

DEVICE

Spectra Optia® Collection Set

Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator

Sponsors & Collaborators

  • Terumo BCT

    collaborator INDUSTRY

  • Chugai Pharma USA

    collaborator INDUSTRY

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Principal Investigators

  • Johannes C Fischer, MD · Heinrich Heine University Hospital Duesseldorf

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01901458 on ClinicalTrials.gov